Basal/HER2 breast carcinomas: Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)

High rates of inherent primary resistance to the humanized monoclonal antibody trastuzumab (Herceptin) are frequent among HER2 gene-amplified breast carcinomas in both metastatic and adjuvant settings. The clinical efficacy of trastuzumab is highly correlated with its ability to specifically and eff...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Martin-Castillo, Begoña, Oliveras-Ferraros, Cristina, Vazquez-Martin, Alejandro, Cufí, Silvia, Moreno, José Manuel, Corominas-Faja, Bruna, Urruticoechea, Ander, Martín, Ángel G., López-Bonet, Eugeni, Menendez, Javier A.
Format: Artigo
Jezik:Inglês
Izdano: Landes Bioscience 2013
Teme:
Perspective
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575452/
https://ncbi.nlm.nih.gov/pubmed/23255137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.23274
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki